# EDGAR Filing Document

**Accession Number:** 0001203301
**File Stem:** 0001104659-26-037181
**Filing Date:** 2026-3
**Character Count:** 16410
**Document Hash:** f65ce6f2be2b87f4d9639b85c2cef5a8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-037181.hdr.sgml**: 20260330

**ACCESSION NUMBER**: 0001104659-26-037181

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260330

**DATE AS OF CHANGE**: 20260330

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** USANA HEALTH SCIENCES INC
- **CENTRAL INDEX KEY:** 0000896264
- **STANDARD INDUSTRIAL CLASSIFICATION:** MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 870500306
- **STATE OF INCORPORATION:** UT
- **FISCAL YEAR END:** 0103

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-55565
- **FILM NUMBER:** 26816484

**BUSINESS ADDRESS:**
- **STREET 1:** 3838 WEST PARKWAY BLVD.
- **CITY:** SALT LAKE CITY
- **STATE:** UT
- **ZIP:** 84120-6336
- **BUSINESS PHONE:** 8019547100

**MAIL ADDRESS:**
- **STREET 1:** 3838 WEST PARKWAY BLVD.
- **STREET 2:** 3838 WEST PARKWAY BLVD.
- **CITY:** SALT LAKE CITY
- **STATE:** UT
- **ZIP:** 84120-6336

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** USANA INC
- **DATE OF NAME CHANGE:** 19930125
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** WENTZ MYRON W
- **CENTRAL INDEX KEY:** 0001203301

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**MAIL ADDRESS:**
- **STREET 1:** C/O STERLING FINANCIAL GROUP
- **STREET 2:** 4525 SOUTH WASATCH BLVD, SUITE 250
- **CITY:** SALT LAKE CITY
- **STATE:** UT
- **ZIP:** 84124

## Exhibit 99.1

**EXHIBIT 1**

**JOINT FILING AGREEMENT**

Each of the undersigned hereby agrees that this Amendment No. 11 to the statement on Schedule 13D is being filed with the Securities and Exchange Commission on behalf of each of the undersigned pursuant to Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.

Date: March 30, 2026

---

| | |
|:---|:---|
| **GULL GLOBAL LIMITED** | **GULL GLOBAL LIMITED** |
| By: | /s/ Valarie A. Hing |
| Name: | Valarie A. Hing |
| Title: | Attorney in Fact |

---

---

| | |
|:---|:---|
| **MYRON W. WENTZ** | **MYRON W. WENTZ** |
| By: | /s/ Valarie A. Hing |
| Name: | Valarie A. Hing |
| Title: | Attorney in Fact |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 11)**

**USANA Health Sciences, Inc.**

*(Name of Issuer)*

**COMMON STOCK, $0.001 par value per share**

*(Title of Class of Securities)*

**—**

*(CUSIP Number)*

**Dr. Myron W. Wentz**<br>c/o Sterling Financial Group<br>4525 South Wasatch Blvd, Suite 250<br>Salt Lake City UT 84124<br>(212) 696-6943

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**03/26/2026**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Gull Global Limited** | Name of reporting person<br>**Gull Global Limited** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**C5** | Citizenship or place of organization<br>**C5** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**7408345.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**7408345.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**7408345.00** | Aggregate amount beneficially owned by each reporting person<br>**7408345.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**40.1%** | Percent of class represented by amount in Row (11)<br>**40.1%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Myron W. Wentz** | Name of reporting person<br>**Myron W. Wentz** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**U7** | Citizenship or place of organization<br>**U7** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**7408345.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**7408345.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**7408345.00** | Aggregate amount beneficially owned by each reporting person<br>**7408345.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**40.1%** | Percent of class represented by amount in Row (11)<br>**40.1%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
COMMON STOCK, $0.001 par value per share

**(b) Name of Issuer:**
USANA Health Sciences, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
3838 West Parkway Boulevard, Salt Lake City, UT, 84120

Explanatory Note:

This Amendment No. 11 ("Amendment No. 11") amends and restates the Schedule 13D originally filed with the Securities and Exchange Commission (the "Commission") on May 23, 2008 (the "Original Schedule 13D" and as amended from time to time, including by this Amendment No. 11, "Schedule 13D") by Myron W. Wentz ("Dr. Wentz") and Gull Holdings, Ltd., an Isle of Man company indirectly owned and controlled by Dr. Wentz ("Gull Holdings"), together with certain other reporting persons named therein (Dr. Wentz, Gull Holdings and such other reporting persons, collectively, the "Original Reporting Persons"), and amended and restated by Amendment No. 1 thereto filed on May 22, 2018, and further amended by Amendment No. 2 thereto filed on June 1, 2018, Amendment No. 3 thereto filed on August 7, 2018, Amendment No. 4 thereto filed on October 2, 2018, Amendment No. 5 thereto filed on February 11, 2020, Amendment No. 6 thereto filed on May 8, 2020, Amendment No. 7 thereto filed on August 24, 2020, Amendment No. 8 thereto filed on March 11, 2021, Amendment No. 9 thereto filed on August 13, 2021, and Amendment No. 10 thereto filed on November 22,2021, each jointly filed by Dr. Wentz and Gull Global Limited ("Gull Global" and together with Dr. Wentz and as applicable, Gull Holdings, the "Reporting Persons"), relating to the common stock, par value $0.001 per share (the "Shares"), of USANA Health Sciences, Inc., a Utah corporation (the "Issuer"). This Amendment No. 11 reflects changes to items 2, 4, 5 and 7 of the Schedule 13D.

**Item 4. Purpose of Transaction**

On May 13, 2008, Dr. Wentz, Gull Holdings, Ltd., an Isle of Man company indirectly owned and controlled by Dr. Wentz ("Gull Holdings"), together with certain other persons (Dr. Wentz, Gull Holdings and such other persons, collectively, the "Original Reporting Persons") announced their intention to commence a tender offer (the "Offer") to purchase all of the outstanding Shares of the Issuer not owned by the Original Reporting Persons for $26.00 per share in cash through Unity Acquisition Corp., a newly formed acquisition vehicle ("Unity Acquisition"). On July 16, 2008, Gull Holdings and Unity Acquisition issued a press release announcing the termination of the Offer and disclosing that no Shares were accepted for payment by the Purchaser in connection with the Offer. As a result of the termination of the Offer on July 16, 2008, the Original Reporting Persons ceased to be a group (as disclosed in Item 11 of Amendment No. 8 to the Schedule TO filed by the Original Reporting Persons with the Commission on July 16, 2008 in connection with the Offer) and the Original Reporting Persons other than Dr. Wentz and Gull Holdings ceased to be reporting persons for purposes of this Schedule 13D.

From July 16, 2008 through November 13, 2013, Gull Holdings sold an aggregate of 1,263,285 Shares (not including Shares sold in cashless exercises, or following receipt upon exercise, of equity compensation Options (as defined below) and SSARs (as defined below) in open market transactions for aggregate gross proceeds of approximately $53,472,263.81.

On July 21, 2008, the Issuer granted to Dr. Wentz equity incentive compensation in the form of stock-settled stock appreciation rights relating to 500,000 Shares (the "SSARs"), with an exercise price of $26.06 per Share. At various times between September 14, 2012 and March 4, 2014, Dr. Wentz exercised the SSARs, which had an aggregate market value of $25,298,771.50 at the time of exercise, and received an aggregate of 233,342 Shares (which were sold in open market transactions in connection with settlement of such exercises).

Between November 2013 and April 2015, Dr. Wentz changed the form of his indirect ownership of the Shares deemed beneficially owned by him by causing Gull Holdings to transfer all of the Shares held by it to Gull Global (the "Gull Reorganization"). To effect the Gull Reorganization, (i) on or about November 29, 2013 Gull Global, which at the time was indirectly wholly owned by the Gull Trust and controlled by Dr. Wentz, acquired 131,788 Shares as a contribution from Gull Holdings, and Gull Global thereby became a reporting person for purposes of this Schedule 13D (Gull Global in such capacity, and together with Dr. Wentz and, as applicable, Gull Holdings, the "Reporting Persons"), (ii) on or about February 20, 2014, Gull Global acquired 100% of the share capital of Gull Holdings, and thereby acquired indirect beneficial ownership of the remaining Shares owned directly by Gull Holdings, and (iii) on or about April 1, 2015, Gull Holdings transferred to Gull Global 6,443,322 Shares and Gull Holdings ceased to be a reporting person for purposes of this Schedule 13D.

From time to time between April 9, 2014 through June 24, 2024, Gull Global sold an aggregate of 4,083,419 Shares (not including Shares sold in cashless exercises, or following receipt upon exercise, of equity compensation Options and SSARs) in open market transactions for aggregate gross proceeds of approximately $367,184,913.48.

Between December 4, 2014 and December 9, 2014 Dr. Wentz exercised, in cashless exercise transactions, options for 280,000 Shares, which he had been granted as equity compensation in 2005, which had an aggregate market value of $28,876,643.71 at the time of exercise and resulted in aggregate net cash proceeds of $12,534,370.59 to Dr. Wentz. The options had an exercise price of $39.18 per share.

From time to time between May 7, 2009 and September 3, 2025 the Reporting Persons also made charitable donations and other gifts of an aggregate of 1,313,171 Shares.

Since the termination of the Offer in 2008, the Reporting Persons have held (and, until Gull Holdings ceased to be a reporting person for purposes of this Schedule 13D, Gull Holdings held), and the Reporting Persons intend to continue to hold, their Shares for investment purposes. However, the Reporting Persons have sold and will continue to sell, some of their Shares through sales in the open market, in privately negotiated transactions or otherwise, on such terms and at such times as the Reporting Persons may deem advisable, for liquidity purposes. Some of such sales have been made pursuant to Rule 10b5-1 trading plans. The Reporting Persons also expect to continue to make charitable donations of Common Stock.  In addition, the Reporting Persons may formulate plans or proposals for, hold discussions with the Issuer's management, the Issuer's Board of Directors, the Issuer's stockholders and other parties about, and reserve the right to explore, or make plans or proposals relating to, transactions, discussions or actions which relate to or would result in any of the matters specified in clauses (a) through (j) of Item 4 of Schedule 13D. The Reporting Persons' consideration or discussion of any action would be based on their own assessment of various relevant considerations and any subsequent developments affecting the Issuer and its prospects.

**Item 5. Interest in Securities of the Issuer**

**(a)**
Gull Global is the direct beneficial owner of 7,408,345 Shares, representing approximately 40.1% of the outstanding Shares, based on 18,456,935 Shares outstanding as of March 13, 2026 as reported by the Issuer in its Annual Report on Form 10-K filed with the Commission on March 16, 2026. Dr. Wentz is deemed to be the beneficial owner of the 7,408,345 Shares held directly by Gull Global, representing approximately 40.1% of the outstanding Shares,.

To the best of the Reporting Persons' knowledge, none of the other persons identified in Item 2 beneficially owns any Shares of the Issuer.

**(b)**
The Reporting Persons share the power to vote or direct the vote of the Shares beneficially owned by them, and the power to dispose of or direct the disposition of such Shares.

**(c)**
Neither the Reporting Persons nor, to the best of the Reporting Persons' knowledge, any person named in Item 2 of the Schedule 13D, has effected any transactions in Shares during the 60-day period prior to the date of this Amendment No. 11.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

Except as otherwise set forth in this Schedule 13D, none of the Reporting Persons has any contract, arrangement, understanding or relationship (legal or otherwise) with any person with respect to any securities of the Issuer, including but not limited to, any contract, arrangement, understanding or relationship concerning the transfer or voting of any securities of the Issuer, finder's fees, joint ventures, loan or option arrangements, puts or calls, guaranties of profits, division of profits or loss or the giving or withholding of proxies.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Gull Global Limited

**Signature:** /s/ Valarie A. Hing

**Name/Title:** Valarie A. Hing/Attorney in Fact

**Date:** 03/30/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Myron W. Wentz

**Signature:** /s/ Valarie A. Hing

**Name/Title:** Valarie A. Hing/Attorney in Fact

**Date:** 03/30/2026